Nutlin-3, a p53-Mdm2 antagonist for nasopharyngeal carcinoma treatment

(Bentham Science Publishers) Nasopharyngeal carcinoma (NPC) is a form of head and neck cancer that is highly prevalent among men in the populations of Southern China and Southeast Asia. This review will discuss the potential use of Nutlin-3 as a p53-activating drug and the future directions of its clinical research for NPC treatment.